Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers
Early-stage (I-III) and de novo stage IV breast cancers shared a similar prevalence of targetable genomic alterations and overall genomic landscape. HRDsig identified approximately 16% of breast cancers without g/sBRCA/gPALB2 alteration that might potentially benefit from PARP inhibitors or platinum-based treatments and should be tested in future clinical studies.
Authors
- Lajos Pusztai (ORCID: https://orcid.org/0000-0001-9632-6686)
- Ethan Sokol (ORCID: https://orcid.org/0000-0002-5480-8473)
- Mia Levy (ORCID: https://orcid.org/0000-0002-5944-2730)
- Russell W. Madison (ORCID: https://orcid.org/0000-0002-7838-2526)
- Richard S.P. Huang (ORCID: https://orcid.org/0000-0001-8395-5168)
- Alexa B. Schrock (ORCID: https://orcid.org/0000-0003-0106-9096)
- Mariya Rozenblit (ORCID: https://orcid.org/0000-0003-0244-429X)
- Kuei‐Ting Chen
- June E Jeon (ORCID: https://orcid.org/0009-0006-1887-5798)
Institutions
- Greenwich Hospital (US)
- Yale Cancer Center (US)
- Foundation Medicine (United States)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf089
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- Breast Cancer Research Foundation